Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan

Toshihiro Sato,Shinjiro Kodama,Keizo Kaneko,Junta Imai,Hideki Katagiri

EMERGING INFECTIOUS DISEASES（2022）

引用 10|浏览5

暂无评分

摘要

Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor-associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.

查看译文

关键词

COVID-19,Japan,SARS-CoV-2,coronavirus disease,coronaviruses,immune checkpoint inhibitor,mRNA vaccine,nivolumab,respiratory infections,second SARS-CoV-2 vaccination,severe acute respiratory syndrome coronavirus 2,type 1 diabetes mellitus,vaccines,virus,zoonoses

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要